CD 44 is of Functional Importance for Colorectal Cancer Stem Cells
Lei Du,Hongyi Wang,Leya He,Jingyu Zhang,Biyun Ni,XiaohuiWang,HaijingJin,N. Cahuzac,MaryamMehrpour,Youyong Lu,Quan Chen
Abstract:Purpose:Both CD44 and CD133 were reported as putative markers for isolating colorectal cancer stem cells (CSC). It remains to be resolved if both of these markers are of functional importance for colorectal CSC. Experimental Design:The expressionof CD44 andCD133 innormal colonic tissues andprimary colorectal cancer was assessed by immunohistochemistry in a series of 60 patients on tissue microarray sections. Both in vitro clonogenic and in vivo tumorigenic assay were applied tomeasure CSC activities from the cells isolated from patients. Lentiviral RNA interference was used to stably knock down CD44 or CD133 in colorectal cancer cells from patients. Results:We found that CD44 cells displayed clustered growth and they did not colocalize with CD133 cellswithin colorectal cancer. As fewas100CD44 cells fromapatients’ tumor initiated a xenograft tumor in vivo. A single CD44 cell from a tumor could form a sphere in vitro which has characteristic stem cell properties and was able to generate a xenograft tumor resembling the properties of the primary tumor. Knockdown of CD44, but not CD133, strongly prevented clonal formation and inhibited tumorigenicity in xenograft model. Conclusions:These results indicate that CD44 is a robustmarker and is of functional importance for colorectal CSC for cancer initiation. Increasing evidence suggests that there is a small subset of cells, called cancer stem cells (CSC), that are responsible for cancer initiation and development (1). The concept of CSC emerged decades ago, and the best evidence came from acute myeloid leukemia in which the rare CD34CD38 population was capable of propagating acute myeloid leukemia in a xenograft transplant system (2, 3). It is believed that CSC has the characteristics of normal adult stem cells including the selfrenewal property and multipotency for differentiation into distinct types of cells (4, 5). It is a technical challenge to identify and to characterize the cancer-initiating cells with CSC properties due to the rarity of CSC in the tissue of origin and the lack of specific markers. Recently, CSC has been described in several solid tumors (6). These studies used putative stem cellmarkers or side populations to isolate unique subsets of cancer cells from different types of tumors. Indeed, these cells had a higher capacity to form clones in vitro and to generate xenograft tumors in immunodeficient mice (7). These markers included CD44, CD133, CD24, and CD166 that are also expressed in other types of normal cells. Among these markers, both CD44 and CD133 were widely used for isolating CSC from solid tumors. CD44 is a transmembrane glycoprotein which participates in many cellular processes, including growth, survival, differentiation, and motility (8–10). It is a unique adhesion molecule and plays a role in cancer cell migration and matrix adhesion in response to a cellular microenvironment, thus enhancing cellular aggregation and tumor cell growth (11). CD44 cells were breast CSC which possessed higher tumorigenicity and metastatic potential (12). CD44 marker was also used to isolate prostate CSC (13, 14), pancreatic CSC (15), and colorectal CSC (16). CD133 is also a cell surface transmembrane glycoprotein which exists in the cholesterol-rich domain of lipid rafts. Although its cellular function is not clear, CD133 is an important marker for a number of different CSC lineages (17). CD133 was used to isolate CSC from brain (18, 19), prostate (14), liver carcinoma (20), and colon carcinoma (21, 22). In several independent reports, both CD44 and CD133 were used as markers for isolating colorectal CSC. This raises the question of whether both markers are applicable to colorectal CSC. It also remains to be resolved if these markers are of functional importance for colorectal CSC. Clarification of this question and a better understanding of the properties of CSC may be useful to develop better therapeutic approaches to fight cancer. Here, we provide evidence showing that Human Cancer Biology Authors’Affiliations: Joint Laboratory of Apoptosis and Cancer Biology, the State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, and College of Life Sciences, Nankai University, Graduate University of the ChineseAcademy of Sciences, Laboratory of Molecular Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China, Cancer Research Center,Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology,Wuhan, China, and INSERM U756, Faculte¤ de Pharmacie, Universite¤ Paris-Sud, ChatenayMalabry, France Received 4/21/08; revised 6/18/08; accepted 6/18/08. Grant support:A key project from the ChineseAcademyof Sciences KSCX2-YWR-02, 973 project 2007CB914800, 2009CB521808, and 2007CB507400 (Q. Chen), and 973 project 071JE11232 (L. Du). Note: N. Cahuzac is supported by the French Embassy. Supplementary data for this article are available at Clinical Cancer Research Online (http :// clincancerres.aacrjournals.org/). Requests for reprints: Quan Chen,The Laboratory of Apoptosis and Cancer Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, P.R. China. Phone : 86-10-6480-7321; Fax : 86-10-6480-7321; E-mail : chenq@ ioz.ac.cn or Youyong Lu, Laboratory of Molecular Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing100142, P.R. China. Phone: 86-10-8819-6765; E-mail: yongylu@public.bta.net.cn. F2008 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-08-1034 www.aacrjournals.org Clin Cancer Res 2008;14(21) November1, 2008 6751 CD44-positive and CD133-positive cells do not colocalize in the same region of colorectal cancer tissues. A single cell can form a sphere in vitro which can initiate a xenograft tumor resembling the properties of primary tumors. Knockdown of CD44, but not CD133, strongly prevents the initiation of a tumor in vivo. Materials andMethods Patients, reagents, and animals. Sixty fresh colorectal cancer and matched normal colon samples were collected from the tumor bank of Beijing Cancer Hospital (Beijing, China) and Tongji Hospital (Wuhan, China), as approved by the Research Ethics Board at the Beijing Institute for Cancer Research. The patients were fully informed and in agreement with the collection of clinical samples. All antibodies used included CD44 (DF1485, Santa Cruz, with 0.1% sodium azide), CD44 (2C5, R&D), CD44-FITC (G44-26, BD PharMingen), CD133 (AC133, Miltenyi, with 0.1% sodium azide), CK20 (Ks20.8, DAKO), CDX2 (AMT28, ZSBio), bromodeoxyuridine (BrdUrd, 3D4, BD PharMingen), and Oct3/4 (C-10, Santa Cruz). Trizol and the reverse transcriptase kit were purchased from Invitrogen, other reagents were purchased from Sigma unless specified otherwise. Four-week-old female nude mice (BALB/c-nu/nu) were purchased from the Chinese Academy of Military Medical Sciences and maintained in standard conditions according to institutional